Independent Research
SMMT Analysis
4 pieces of research on Summit Therapeutics Inc.. We find the signal management buried in the earnings call.
3signal analyses
1news briefs
latest: Sep 29, 2026
Signal Analysis (3)
Analysis
Summit Therapeutics Phase III Beats Keytruda, Burns $458M
Summit Therapeutics' ivonescimab achieved Phase III superiority over pembrolizumab in non-small cell lung cancer, posting 30.8 months median overall survival ve…
Read analysis →Analysis
Summit's NSCLC Data Tops Keytruda, Cash Runway Tightens
Summit Therapeutics' ivonescimab outperformed Keytruda in a China lung cancer trial, a major clinical win. Yet the company raised equity twice in six weeks—sign…
Read analysis →Analysis
Summit Therapeutics CEOs Spend $100M Buying Own Stock
Summit Therapeutics co-CEOs Robert Duggan and Mahkam Zanganeh each bought 3,810,000 shares at $13.12 on June 12, committing a combined $100 million of personal …
Read analysis →